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Abstract
The reduced production or activity of the cysteine-rich glycoprotein progranulin is responsible for about 20% of cases of
familial frontotemporal dementia. However, little is known about the molecular mechanisms that govern the level and
secretion of progranulin. Here we show that progranulin is expressed in mouse cortical neurons and more prominently in
mouse microglia in culture and is abundant in the endoplasmic reticulum (ER) and Golgi. Using chemical crosslinking,
immunoprecipitation, and mass spectrometry, we found that progranulin is bound to a network of ER Ca2+-binding
chaperones including BiP, calreticulin, GRP94, and four members of the protein disulfide isomerase (PDI) family. Loss of
ERp57 inhibits progranulin secretion. Thus, progranulin is a novel substrate of several PDI family proteins and modulation of
the ER chaperone network may be a therapeutic target for controlling progranulin secretion.
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Introduction
Frontotemporal lobar degeneration (FTLD), the most common
cause of dementia before the age of 60 years [1], causes behavioral
and cognitive abnormalities, and up to 40% of patients have a family
history of dementia [1,2]. Mutations in several genes have been
implicated in the pathogenesis of familial FTLD, including pro-
granulin (PGRN), a secreted protein whose functions in the nervous
system are poorly understood [3,4]. PRGN mutations are a major
cause of the disease, and genetic evidence suggests that haploinsuffi-
ciency is involved, since disease-associated mutations in PGRN often
lead to reduced PGRN production or activity [3–8]. It is not known
how such reductions lead to neurodegeneration. However, molec-
ular interventions that increase PGRN production or secretion from
the remaining wildtype allele are a promising therapeutic strategy for
FTLD caused by PGRN deficiency.
It is likely that the levels of intracellular and secreted PGRN are
regulated through multiple mechanisms. PGRN transcription can
be enhanced by several small molecules, including suberoylanilide
hydroxamic acid, an FDA-approved histone deacetylase inhibitor
[9]. PGRN production and secretion can also be modulated
through post-transcriptional mechanisms. For instance, loss of
microRNA-29b activity increases the levels of intracellular and
secreted PGRN in 3T3 cells [10]. MicroRNA-107 also contributes
to the regulation of PGRN expression [11]. Interestingly, a com-
mon genetic variant, rs5848, in the 39 untranslated region of
human PGRN (hPGRN) mRNA increases the binding and
inhibitory activity of microRNA-659 [12]. Moreover, inhibitors
of vacuolar ATPase and some clinically used alkalizing drugs
increase PGRN production and secretion through a translational
mechanism [13]. Extracellular levels of PGRN are also influenced
by its rate of uptake through sortilin-mediated endocytosis [14,15].
It is not known how PGRN, a secreted and highly glycosylated
protein, is regulated in the endoplasmic reticulum (ER)-Golgi
secretory pathway. hPGRN contains 7.5 granulin domains, each
of which contains 12 cysteines that form six intramolecular
disulfide bonds [16]. In mouse brain, mouse PGRN (mPGRN)
expression increased more than 60-fold in activated microglia
[17], posing a significant challenge for proper folding and efficient
secretion. In this study, through biochemical approaches, we
found that PGRN is a novel substrate of four protein disulfide
isomerase (PDI) family proteins, raising the possibility that modu-
lation of the ER chaperone network may be a therapeutic target
for controlling progranulin secretion.
Results
Identification of PGRN-Interacting Proteins
To identify regulators of PGRN secretion and PGNR-interacting
proteins, we constructed fusion proteins whose expression is con-
trolled by the CMV promoter, including mPGRN-tagged with
alkaline phosphatase (AP) or HA.We transfected these constructs into
HEK293 cells (Invitrogen) and examined the levels of intracellular or
secreted mPGRN by Western blotting with an mPGRN-specific
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antibody (R&D Systems) that does not recognize endogenous
hPGRN in HEK293 cells. mPGRN-HA but not mPGRN-AP was
effectively secreted into the culture medium even though both
constructs contained the mPGRN signal peptide (Fig. 1A).
To facilitate the identification of mPGRN-interacting proteins, we
established stably transfected HEK293 cells expressing mPGRN-
HA. This system enabled us to examine the molecules that
specifically regulate mPGRN secretion, since mPGRN-HA is
controlled by the constitutively active CMV promoter, and
endogenous hPGRN expression is sensitive to many extracellular
stimuli including various transfection agents and is regulated both
transcriptionally and posttranscriptionally (unpublished observa-
tion). Assuming that some proteins exhibit stable physical interac-
tions with PGRN, we treated these cells with the membrane-
impermeable chemical crosslinker bis(sulfosuccinimidyl) suberate
(BS) and the membrane-permeable crosslinker DSS. With DSS but
not BS treatment, a significant fraction of mPGRN showed a slower
mobility as detected by Western blot (Fig. 1B). This experiment did
not identify membrane surface proteins that might be bound with
extracellular mPGRN but revealed a direct interaction between
mPGRN and some proteins that are likely to be intracellular.
To identify these mPGRN-interacting proteins, we used HA
antibody to immunoprecipitate mPGRN-containing protein
complexes after DSS crosslinking and analyzed the proteins by
SDS-PAGE and silver staining (Fig. 2A). It seems that some
proteins were complexed with or crosslinked with mPGRN
(Fig. 2B). The molecular sizes of bands 1–3 were very similar to
that detected by Western blotting with mPGRN-specific antibody
(Fig. 1B) and are therefore likely to be high-molecular-weight
complexes containing proteins covalently crosslinked with
mPGRN. Indeed, mass spectrometry analysis revealed multiple
peptides corresponding to several major Ca2+-binding chaperone
molecules residing in the ER, including BiP, calreticulin, GRP94,
PDI, and the PDI-related proteins ERp57, ERp72, and ERp5
(Table 1). Band 4 was the molecular chaperone HSP70-1, which
was also present in the crosslinked complex in band 3 (Table 1),
indicating a direct interaction between mPGRN and HSP70-1.
PGRN Co-localizes with Several Markers in the Secretory
Pathway
To confirm the biochemical findings, we examined the
subcellular localization of PGRN by immunostaining. In
Figure 1. Biochemical identification of PGRN-interacting proteins. (A) mPGRN-AP or mPGRN-HA fusion protein constructs were stably
transfected into HEK293 cells. Cell lysates or culture medium was analyzed on Western blot with anti-mPGRN antibody. This antibody specifically
recognizes mPGRN but not the endogenous hPGRN in HEK293 cells. b-actin was used as the loading control. (B) Stably transfected HEK293 cells
expressing mPGRN-HA were treated with cross linkers, followed by immunoprecipitation (IP) with HA antibody or control IgG. Immunoisolates were
analyzed on Western blot with anti-mPGRN antibody. UT, untransfected HEK293 cells; ST, stably transfected cells.
doi:10.1371/journal.pone.0026454.g001
Figure 2. Biochemical identification of PGRN-interacting proteins. (A) Description of the experiment in C. mPGRN-HA stably transfected
HEK293 cells were treated with the chemical crosslinker DSS. Immunoprecipitation was performed with an anti-HA antibody. The immunoisolates
were analyzed by SDS-PAGE, which was then silver stained. Specific bands were cut out and analyzed by mass spectrometry. (B) Image of a gel after
silver staining. The identities of bands 1–4 are listed in Table 1.
doi:10.1371/journal.pone.0026454.g002
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HEK293 cells expressing mPGRN, an mPGRN-specific antibody
showed that mPGRN co-localized with several ER proteins, such
as calreticulin, ERp57, and ERp72 (Fig. 3, A–I). To confirm this
finding, we also examined endogenous hPGRN expressed in
HEK293 cells. Indeed, endogenous hPGRN is also co-localized
with ERp72 (Fig. 3, J–L), raising the possibility that PGRN
secretion may be a rate-limiting step.
PGRN Is Expressed from Primary Cortical Neurons and
Microglia But Not by Astrocytes
To examine the expression patterns of PGRN in neural cells, we
isolated primary cortical neurons and glial cells from E18 mouse
embryos. Endogenous mPGRN was detectable in cultured MAP2-
positive cortical neurons (Fig. 4, A–C), consistent with in situ
analysis of mouse brains [18]. mPGRN was not detected in
astrocytes in cultures without neurons but was present in granular
structures in the processes of astrocytes in mixed cortical cell
cultures (Fig. 4, D–F). Further immunostaining analysis indicated
that these granular structures seemed to be inside vesicles
expressing the lysosomal marker LAMP1 (Fig. 4, G–I), raising
the possibility that astrocytes take up mPGRN secreted by neurons
and transport it to lysosomal compartments.
mPGRN was prominently expressed in cultured microglia from
postnatal day 3–4 mouse brains (Fig. 4, J–L). The staining signal
was specific to mPGRN, since no signal was observed when the
same antibody was used on microglia from GRN knockout mice
[19] (Fig. 4, M–O). In microglia, mPGRN largely co-localized
with the ER marker calreticulin (Fig. 5, A–C) and partly co-
localized with the cis-Golgi marker GM130 (Fig. 5, D–F) and the
trans-Golgi marker TGN38 (Fig. 5, G–I). Thus, a large fraction of
PGRN remains in the intracellular ER-Golgi secretory pathway,
suggesting that its posttranslational processing and secretion in
neurons and microglia are inefficient and tightly regulated.
ERp57 and ERp5 Promote mPGRN Secretion
PGRN expression is more than 60-fold higher in activated
microglia than in resting microglia in vivo [17]. By using stably
transfected HEK293 cells expressing mPGRN under control of the
constitutively active CMV promoter, we were able to examine the
specific effects of PGRN-interacting proteins on post-tanscrip-
tional regulation of overexpressed mPGRN such as its secretion.
Since BiP, GRP94, and calreticulin are all key ER chaperones
essential for cell viability and mammalian development [20], we
decided to examine identified PDI family proteins that exhibit
distinct substrate specificities [21–23]. For instance, we used
siRNA to knock down the expression of endogenous ERp57, a
PDI protein that regulates the secretion of glycosylated proteins
(Fig. 6A). Because PDI is an essential gene, we didn’t perform
similar analysis on this gene. Two independent siRNA sequences
also effectively reduced ERp57 expression in HEK293 cells
(Fig. 6A) with minimal effect on mPGRN mRNA expression, as
shown by real time RT-PCR (Fig. 6B). Both siRNAs also reduced
secretion of mPGRN in the culture medium (Fig. 6, C and D).
This finding is consistent with reports that ERp57 is required for
the proper secretion of several other substrates [22]. Examination
of intracellular progranulin under native non-denaturing condi-
tions showed one prominent mPGRN band that didn’t reveal a
difference in its folding state before and after ERp57 knockdown
(data not shown), suggesting that misfolded PGRN due to blockage
of its secretion is likely degraded. Indeed, immunostaining
experiment didn’t detect a difference in mPGRN subcellular
localization after ERp57 knockdown (data not shown).
Another PGRN-interacting PDI member identified from our
biochemical analysis is ERp5 (Table 1). Similar to ERp57,
knockdown experiments show that ERp5 also promotes PGRN
secretion (Fig. 6E–G), indicating their overlapping functions in this
process.
Discussion
PDI family proteins in the ER are responsible for the proper
formation of intramolecular disulfide bonds through thiol-disulfide
oxidation, reduction, and isomerization reactions on newly synthe-
sized membrane proteins and secreted proteins [21–23]. Humans
have 20 PDIs, which differ in the number and arrangement of
thioredoxin-like domains, and the precise functions and substrate
specificity for most of these PDIs are unclear. One of the most well-
studied is ERp57, which is glycoprotein-specific and interacts with
the lectin-like chaperones calnexin and calreticulin [23]. PGRN is a
secreted and highly glycosylated protein with 88 cysteines [16,24].
Thus, the identification of its physical interactions with PDI
members and calreticulin in this study is not unexpected. Acute
knockdown of ERp57 reduced PGRN secretion (Fig. 6), consistent
with reports that ERp57 is essential for the proper folding of many
membrane and secreted proteins and their transport through the
ER-Golgi pathway [25–27]. Our findings here also indicate that
progranulin is a previously unknown substrate for ERp5.
Our results also indicate that PGRN is regulated by a network
of ER molecular chaperones as a novel substrate of ERp72.
Although the exact molecular function of ERp72 is largely
unknown, structural analyses suggest that its substrate specificity
differs from that of PDI or ERp57 [28,29]. ERp72 seems to have a
narrow substrate specificity but exerts no detectable effects on the
secretion of some tested substrates [27]. Indeed, we generated
ERp72 knockout mice and found that progranulin secretion from
cultured neurons was not affected (unpublished data).
PGRN expression is markedly elevated in many physiological
and pathological conditions, such as cell proliferation, wound
healing, tumorigenesis, and brain injury [16,17]. Of particular
interest, the intracellular level of PGRN expression is more than
60-fold higher in activated microglia than in resting microglia in
mouse brain [17]. This finding, together with other reports ([3,4]
and our analysis on subcellular localization of PGRN in culture,
raises the possibility that PGRN folding and secretion are
inefficient and tightly regulated. Thus, the molecular chaperones
identified this study may help us understand the molecular
machineries that regulate the posttranslational regulation of
PGRN in certain pathological conditions.
In frontotemporal dementia patients with PGRN deficiency,
one promising therapeutic approach is to increase production
and/or secretion of PGRN from the remaining wildtype allele.
Our findings raise the possibility that modulating the ER
chaperone network to increase the level of extracellular PGRN
may be a novel strategy for treating these patients.
Table 1. Identification of proteins that are crossed-linked
with progranulin.
Band Size Identified Proteins
1 200 kD BiP, Calreticulin, GRP94, PDI, ERp57, ERp72, ERp5
2 150 kD BiP, Calreticulin, PDI, ERp57, ERp5
3 135 kD BiP, Calreticulin, GRP94, HSP70-1, PDI, ERp57, ERp5
4 70 kD HSP70-1
doi:10.1371/journal.pone.0026454.t001
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Materials and Methods
Ethics Statement
All animal works have been conducted according to relevant
national and international guidelines with the protocol (Docket #
2193–10) approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Massachusetts Medical
School.
Animals and Cell Cultures
PGRN2/2 mice were obtained from Kayasuga et al. [30].
Primary microglial cultures were obtained from PGRN2/2 mice
and their littermates at 3–4 days of age. Cerebral cortices were
dissected and incubated in 0.25% trypsin for 20 min at 37uC.
Cells were dissociated in plating medium (Eagle’s MEM
supplemented with 10% FBS, 0.45% glucose, 0.11 mg/ml
sodium pyruvate, 0.2 mM glutamine, 1% penicillin/streptomy-
Figure 3. Co-localization of mPGRN-HA with its interacting proteins in HEK293 cells. (A, D, G) Subcellular localization of mPGRN in
HEK293 cells. (B, Co-immunostaining of cells in (A) with anti-calreticulin (Calr) antibody. (C) the merged image of (A) and (B). (E) Co-immunostaining
of cells in (D) with anti-ERp57 antibody. (F) The merged image of (D) and (E). (H) Co-immunostaining of cells in (G) with anti-ERp72 antibody. (I)
Merged image of (G) and (H). The mPGRN antibody did not recognize endogenous hPGRN in HEK293 cells. (J) Subcellular localization of endogenous
hPGRN in HEK293 cells. (K) Subcellular localization of endogenous ERp72 in HEK293 cells. (L) Merged image of (J) and (K) indicates that endogenous
hPGRN also largely co-localizes with ERp72. Note that the size of scales bars in J–K are different from A–I and mPGRN is overexpressed in A–I and
shows a stronger signal in the ER. Scale bars: A–I, 10 mm; J–L, 10 mm.
doi:10.1371/journal.pone.0026454.g003
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cin) and plated in poly-L-lysine–coated flasks. Three hours
later, the plating medium was replaced with DMEM containing
10% FBS and 1% penicillin/streptomycin. At day 10, microglia
cells were harvested and plated on poly-L-lysine–coated cover-
slips and cultured for 2–3 days in macrophage serum-free
medium (Gibco).
Figure 4. Expression of endogenous PGRN in different brain cell types. (A–C) mPGRN is expressed in MAP2-positive cultured mouse cortical
neurons. (D–F) mPGRN is present in the processes of astrocytes in mixed brain cell cultures. (G–I) mPGRN seems to be localized in LAMP1-positive vesicles.
(J–L) mPGRN is highly expressed in Iba1-positive culturedmousemicroglia. (M–O) Anti-mPGRN specifically recognizes the endogenousmPGRN protein since
the immunostaining signal is absence in Iba1-positive microglia (M) isolated from GRN knockout mice (N). Scale bar: 20 mm for all panels except G–I (3 mm).
doi:10.1371/journal.pone.0026454.g004
Progranulin as a Substrate of PDI Family Proteins
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Primary cortical neurons were isolated from embryonic day (E)
18 mice as described for microglia cells, except that, cells were
plated on poly-L-lysine–coated coverslips after dissociation and
cultured for 7 days in Neurobasal medium supplemented with 2%
B-27, 0.2 mM glutamine, and 1% penicillin/streptomycin.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde (pH 7.4) for 10 min
and incubated in 0.1% saponin and 3% BSA for 30 min. Next,
cells were incubated in primary antibodies for 1 h at room
temperature. The primary antibodies used were mouse anti-trans-
Golgi network 38 (TGN38) (Affinity Reagents; 1:100), mouse anti-
GM130 (BD Bioscience; 1:350), mouse anti-MAP2 (Sigma; 1:200),
mouse anti-LAMP1 (Stressgen; 1:200), sheep anti-PGRN (R & D
Systems, 1:100), rabbit anti-a-Iba1 (Wako; 1:350), rabbit anti-
calreticulin (Sigma; 1:250), rabbit anti-glial fibrillary acidic protein
(Dako; 1:1000), rabbit anti-ERp57 (1:3000, a kind gift from Dr. D.
Williams), goat anti-hPGRN (Alexis Biochemicals; 1:100), rat anti-
hemagglutinin (HA) (Roche; 1:200). After three washes with PBS,
the cells were incubated with AlexaFluor secondary antibodies
(Invitrogen; 1:200) for 1 h at room temperature. Immunostained
cells were examined with a confocal microscope (D-Eclipse C1,
Nikon).
Chemical Cross-Linking and Immunoprecipitation
HEK293 cells (Invitrogen) expressing mPGRN-HA or vector
were treated with Ca2+- and Mg2+-free PBS containing 1 mM
disuccinyl suberate (DSS) (Pierce) or 1 mM bis[sulfosuccinimidyl]
suberate (BS) (Pierce) for 30 min at room temperature. The cross-
link reactions were quenched with 50 mM Tris (pH7.4), and cells
were washed with PBS and lysed in immunoprecipitation buffer
consisting of 50 mM Tris-HCl, 150 mM NaCl, 0.5% Triton X-
100, 1 mM EDTA, 10 mM NaF, 15% glycerol, protease inhibitor
cocktail (Pierce), and Halt phosphatase inhibitor cocktail (Pierce).
Total protein lysate (1 mg) was incubated with 3 mg of anti-HA
antibody (3F10, Roche) overnight at 4 uC and then with protein
G-agarose for 3 h. Immunoprecipitates were washed with
immunoprecipitation buffer and eluted in sample buffer. The
samples were subjected to SDS-PAGE and immunoblot analysis or
stained with silver stain for mass spectrometry analysis.
Gene Knockdown and Western Blotting
mPGRN-HA stable cells were seeded on 12-well plates (26105
cells/well), transfected with negative control siRNA (Qiagen),
siRNA directed against PDIA3/ERp57 (Qiagen) using Lipofecta-
mine RNAiMax (Invitrogen) or vector-based PDIA6 siRNAs using
Lipofectamine RNAiMax (Invitrogen). The medium was changed
48 h after transfection, and medium and cells were harvested 16 h
later. The cells were lysed in RIPA buffer and centrifuged at
12,000 rpm for 10 min. Both lysates and medium were subjected
to SDS-PAGE and immunoblot analysis with rabbit anti-ERp57
(1:3000, a kind gift from Dr. D. Williams), anti-ERp5 (1:2000,
Abcam), sheep anti-mPGRN (R&D Systems; 1:1000), mouse anti-
b-actin (Sigma; 1:5000), mouse anti-b-tubulin (Developmental
Studies Hybridoma Bank; 1:200), mouse anti-GAPDH (Millipore;
1:2500), rat anti-HA (1:2000, Roche). Immunoblots were
developed with SuperSignal West Pico chemiluminescent sub-
strates (Thermo Scientific).
Figure 5. Subcellular localization of endogenous mPGRN in cultured primary microglia. (A, D, G) Immunostaining of endogenous
mPGRN in cultured primary microglia. (B) immunostaining of the ER marker calreticulin in the microglia in (A). (C) Merged image of (A), and (B). (E)
Immunostaining of the cis-Golgi marker GM130 in the microglia in (D). (F) Merged image of (D) and (E). (H) Immunostaining of the trans-Golgi marker
TGN38 in the microglia in (G). (I) Merged image of (G) and (H). Scale bar: 20 mm.
doi:10.1371/journal.pone.0026454.g005
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Molecular Cloning and RT-PCR
siRNA constructs were generated by cloning annealed oligonu-
cleotides in pSUPER-GFP (Oligoengine) vector with BglII-XhoI
enzyme sites. Total RNA was isolated with an RNeasy kit
(Qiagen), and 500 ng of RNA were reverse transcribed to cDNA
using TaqMan reverse transcription reagents (Applied Biosystems)
following the manufacturer’s instructions. Quantitative PCR was
performed with SYBR Green Master Mix (Applied Biosystems)
and 10 mM of forward and reverse primers. GAPDH was used as a
control probe.
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